ATE271026T1 - Neue sälze von hmg-coa reductase inhibitoren - Google Patents

Neue sälze von hmg-coa reductase inhibitoren

Info

Publication number
ATE271026T1
ATE271026T1 AT99941798T AT99941798T ATE271026T1 AT E271026 T1 ATE271026 T1 AT E271026T1 AT 99941798 T AT99941798 T AT 99941798T AT 99941798 T AT99941798 T AT 99941798T AT E271026 T1 ATE271026 T1 AT E271026T1
Authority
AT
Austria
Prior art keywords
hmg
coa reductase
reductase inhibitors
amine salts
preparation
Prior art date
Application number
AT99941798T
Other languages
English (en)
Inventor
Zlatko Pflaum
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Application granted granted Critical
Publication of ATE271026T1 publication Critical patent/ATE271026T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C07C211/10—Diaminoethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/07—Monoamines containing one, two or three alkyl groups, each having the same number of carbon atoms in excess of three
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99941798T 1998-09-18 1999-09-17 Neue sälze von hmg-coa reductase inhibitoren ATE271026T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9800240A SI20070A (sl) 1998-09-18 1998-09-18 Nove soli inhibitorjev HMG-CoA reduktaze
PCT/IB1999/001554 WO2000017150A1 (en) 1998-09-18 1999-09-17 NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS

Publications (1)

Publication Number Publication Date
ATE271026T1 true ATE271026T1 (de) 2004-07-15

Family

ID=20432331

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99941798T ATE271026T1 (de) 1998-09-18 1999-09-17 Neue sälze von hmg-coa reductase inhibitoren

Country Status (15)

Country Link
US (4) US6583295B1 (de)
EP (2) EP1466886A3 (de)
JP (1) JP3834203B2 (de)
KR (1) KR100699368B1 (de)
CN (1) CN1228304C (de)
AT (1) ATE271026T1 (de)
AU (1) AU765373C (de)
CA (1) CA2343646A1 (de)
DE (1) DE69918697T2 (de)
HU (1) HUP0103007A3 (de)
IL (1) IL142055A (de)
IS (1) IS2113B (de)
NZ (1) NZ509583A (de)
SI (1) SI20070A (de)
WO (1) WO2000017150A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0251582A (ja) * 1988-08-12 1990-02-21 Kyokado Eng Co Ltd 地盤注入用薬液
AU782143B2 (en) * 1998-09-18 2005-07-07 Lek Pharmaceuticals D.D. Crystals of the sodium salt of pravastatin
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI1154979T1 (en) * 1999-02-03 2005-10-31 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6531507B1 (en) 2000-06-09 2003-03-11 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
CZ20031166A3 (cs) * 2000-10-05 2004-04-14 Biogal Gyogyszergyar Rt Sodná sůl pravastatinu, která v podstatě neobsahuje pravastatin lakton a epi-pravastatin a kompozice na její bázi
JP2002121172A (ja) * 2000-10-16 2002-04-23 Sankyo Co Ltd プラバスタチン又はその薬理上許容される塩の精製方法
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
EP1404301A4 (de) * 2001-06-21 2006-03-22 Andrx Pharmaceuticals Inc Pravastatin enthaltende stabile pharmazeutische zusammensetzungen mit kontrollierter freisetzung
JP2003026634A (ja) * 2001-07-17 2003-01-29 Mercian Corp プラバスタチンナトリウム塩の製造方法
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
DE60323835D1 (de) * 2002-06-13 2008-11-13 Novartis Ag Calciumsalze von statinen aus indol
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
WO2005014541A1 (en) * 2003-08-12 2005-02-17 Biocon Limited Novel antihypercholesterolemic compound
EP1562912A2 (de) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Verfahren zur herstellung von rosuvastatin-calcium
RU2315755C2 (ru) * 2003-09-17 2008-01-27 Уорнер-Ламберт Компани Ллс Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005056534A1 (en) 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
EP1709008A1 (de) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salze von hmg-coa-reduktase-inhibitoren und deren verwendung
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
JP2007536373A (ja) 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
US7179916B2 (en) 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
MX2007001558A (es) * 2004-08-06 2008-03-13 Transform Pharmaceuticals Inc Formulaciones novedosas de fenofibrato y metodos de tratamiento relacionados.
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
EP1786414A4 (de) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc Neue pharmazeutische statin-zusammensetzungen und relevante behandlungsverfahren
WO2006072963A1 (en) * 2005-01-10 2006-07-13 Concord Biotech Limited Process for preparing simvastatin from lovastatin amine salts in three steps
EP1851206B1 (de) 2005-02-22 2012-08-15 Teva Pharmaceutical Industries, Ltd. Rosuvastatin und seine salze die frei von rosuvastatin-alkylether sind und ein verfahren zu ihrer herstellung
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
US7868169B2 (en) 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
PL211815B1 (pl) * 2007-11-19 2012-06-29 Inst Chemii Organicznej Polska Akademia Nauk Enzym esteraza lowastatyny osadzony na nośniku nierozpuszczalnym w wodzie, sposób osadzania enzymu, zastosowanie enzymu esterazy lowastatyny osadzonego na nosniku nierozpuszczalnym w wodzie, przepływowy reaktor biokatalityczny ze złożem oraz sposób wytwarzania i/lub oczyszczania symwastatyny
WO2009078033A2 (en) * 2007-12-18 2009-06-25 Themis Medicare Limited Isolation and recovery of simvastatin in lactone form or in the form of an acid salt from the harvested fermentation broth
WO2011089559A1 (en) * 2010-01-22 2011-07-28 Orchid Chemicals And Pharmaceuticals Limited A novel polymorphic form of atorvastatin salts
WO2012063115A2 (en) 2010-11-11 2012-05-18 Jubilant Life Sciences Ltd. Process for the preparation of rosuvastatin calcium via novel amine intermediate
CN114031496A (zh) * 2021-11-30 2022-02-11 广东蓝宝制药有限公司 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
ES493726A0 (es) 1979-07-27 1981-06-16 Sankyo Co Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos.
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS57123140A (en) 1981-01-23 1982-07-31 Sankyo Co Ltd Ml-236b carboxylic acid amine salt and remedy for hyperlipemia containing said salt as active component
JPS57185275A (en) 1981-05-07 1982-11-15 Sankyo Co Ltd Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
US4997848A (en) * 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US5089523A (en) * 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids
US5223415A (en) 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5763653A (en) 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Key intermediates in the manufacture of simvastatin
US5763646A (en) * 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Process for manufacturing simvastatin from lovastatin or mevinolinic acid
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina

Also Published As

Publication number Publication date
JP3834203B2 (ja) 2006-10-18
US20030120086A1 (en) 2003-06-26
DE69918697T2 (de) 2005-07-28
AU765373B2 (en) 2003-09-18
DE69918697D1 (de) 2004-08-19
JP2002526467A (ja) 2002-08-20
CN1228304C (zh) 2005-11-23
US6583295B1 (en) 2003-06-24
EP1114021B1 (de) 2004-07-14
SI20070A (sl) 2000-04-30
IL142055A (en) 2004-06-20
IS2113B (is) 2006-06-15
IS5891A (is) 2001-03-15
US20050049422A1 (en) 2005-03-03
EP1114021A1 (de) 2001-07-11
HUP0103007A2 (hu) 2002-05-29
AU5528599A (en) 2000-04-10
US20080188552A1 (en) 2008-08-07
CA2343646A1 (en) 2000-03-30
EP1466886A2 (de) 2004-10-13
US6838566B2 (en) 2005-01-04
KR20010071959A (ko) 2001-07-31
HUP0103007A3 (en) 2003-10-28
EP1466886A3 (de) 2009-02-25
KR100699368B1 (ko) 2007-03-27
AU765373C (en) 2005-05-26
NZ509583A (en) 2003-10-31
IL142055A0 (en) 2002-03-10
CN1318046A (zh) 2001-10-17
WO2000017150A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
ATE271026T1 (de) Neue sälze von hmg-coa reductase inhibitoren
IL187261A0 (en) Crystals of the sodium salt of pravastatin
IS5939A (is) Stöðug lyfjablanda sem inniheldur HMG-CoA redúktasahemil
ATE284396T1 (de) Verfahren zur bereitstellung von hochreinen hmg- coa reductase hemmer
ATE164886T1 (de) Biochemische reinigung von simvastatin
AU1510800A (en) Process for the preparation of simvastatin and analogs thereof
DK0517413T3 (da) Fermentering af en triol-heptansyre ved mutante stammer af Aspergillus terreus
DE60037687D1 (de) Verfahren zur Rückgewinnung von Statinverbindungen aus einer Fermentationsbrühe
IE842592L (en) Preparing pyranones
CA2053000A1 (en) Biosynthetic production of 6(r)-[2-(8(s)-hydroxy-2(s), 6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydronaphthyl)-ethyl]-4 (r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one triol acid by enzymatic hydrolysis of lovastatin acid using an enzyme derived from__lonostachys compactiuscula
AU2002247944B2 (en) Amorphous Hmg-CoA reductase inhibitors of desired particle size
KR890005080A (ko) HMG-CoA환원효소 억제제
HK1023572A1 (en) An improved process of lactonization in the preparation of statins.
YU88602A (sh) Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže
CO5611117A2 (es) Combinacion de compuestos organicos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1114021

Country of ref document: EP